The final results from DESTINY and similar studies are anticipated to lead to new indications—for example, as of 2025, international guidelines (EAU) are already discussing the possibility of using trastuzumab deruxtecan in HER2-positive urothelial carcinomas, especially after the exhaustion of standard options. The gene discussed is ERBB2; the disease is urothelial carcinoma.